Reuters -- U.S. regulators are reviewing preliminary data suggesting patients taking Abbott Laboratories Inc’s weight loss drug Meridia may have a higher risk of cardiovascular problems, the Food and Drug Administration said on Friday.
Reuters -- U.S. regulators are reviewing preliminary data suggesting patients taking Abbott Laboratories Inc’s weight loss drug Meridia may have a higher risk of cardiovascular problems, the Food and Drug Administration said on Friday.
